Literature DB >> 15515140

Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle.

Eirik Grønevik1, Fredik Vult von Steyern, John Magne Kalhovde, Torunn Elisabeth Tjelle, Iacob Mathiesen.   

Abstract

BACKGROUND: Injection of DNA encoding exogenic proteins into muscle tissue combined with electroporation often results in a transient increase of the encoded protein concentration in the muscle and the blood. The reduction is normally due to an immune response against the exogenic protein but other factors may also be involved. How various electroporation parameters affect the concentration kinetics of syngenic and exogenic proteins is studied in relation to immune response and muscle damage after electroporation-mediated DNA transfer to muscle.
METHODS: Electroporation was applied to mouse quadriceps and rat tibialis anterior muscles after injection of DNA encoding either secreted alkaline phosphatase (SEAP), beta-galactosidase (beta-gal), luciferase or a mouse IgG molecule. Protein concentrations in blood or muscle and antibody responses were measured for a period up to 3 months. Tissue inflammation and muscle cell damage were studied on muscle cross-sections and assessed by measuring the concentrations of creatine phosphokinase (CPK) in blood.
RESULTS: Mice with the highest SEAP concentration in blood at day 7 also had the highest rate of decrease afterwards, the strongest antibody responses against SEAP and the highest acute levels of CPK in blood. DNA-transfected muscle fibers were significantly reduced in number from days 7 to 14. Mononuclear cells surrounded the reporter gene expressing muscle fibers, thus indicating a cellular immune response. When using DNA encoding a syngenic protein the protein concentration in blood was relatively stabile over a 3-month period, but showed different kinetics for various electroporation parameters.
CONCLUSIONS: Our findings suggest that the optimal electroporation parameters for DNA vaccination may be different from the optimal parameters for long-term expression of genes encoding syngenic proteins. Copyright (c) 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15515140     DOI: 10.1002/jgm.650

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  16 in total

1.  Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.

Authors:  Dinah H Amante; Trevor R F Smith; Janess M Mendoza; Katherine Schultheis; Jay R McCoy; Amir S Khan; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Gene Ther Methods       Date:  2015-08       Impact factor: 2.396

2.  Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation.

Authors:  Jinyan Liu; Rune Kjeken; Iacob Mathiesen; Dan H Barouch
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

3.  In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.

Authors:  Qingtao Wang; Wei Jiang; Yuhai Chen; Pengyu Liu; Chunjie Sheng; Shuai Chen; Hui Zhang; Changchuan Pan; Shijuan Gao; Wenlin Huang
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

4.  Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.

Authors:  Nicola Winstone; Aaron J Wilson; Gavin Morrow; Cesar Boggiano; Maria J Chiuchiolo; Mary Lopez; Marina Kemelman; Arielle A Ginsberg; Karl Mullen; John W Coleman; Chih-Da Wu; Sandeep Narpala; Ian Ouellette; Hansi J Dean; Feng Lin; Niranjan Y Sardesai; Holly Cassamasa; Dawn McBride; Barbara K Felber; George N Pavlakis; Alan Schultz; Michael G Hudgens; C Richter King; Timothy J Zamb; Christopher L Parks; Adrian B McDermott
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

5.  In vivo remote delivery of DNA encoding for hypoxia-inducible factor 1 alpha reduces myocardial infarct size.

Authors:  Gabor Czibik; Vladimir Martinov; Arno Ruusalepp; Julia Sagave; Øivind Skare; Guro Valen
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

Review 6.  DNA vaccines, electroporation and their applications in cancer treatment.

Authors:  Si-Hyeong Lee; Sayyed Nilofar Danishmalik; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.

Authors:  Simon R Best; Shiwen Peng; Chi-Mou Juang; Chien-Fu Hung; Drew Hannaman; John R Saunders; T-C Wu; Sara I Pai
Journal:  Vaccine       Date:  2009-07-19       Impact factor: 3.641

8.  DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies.

Authors:  Kyusun Torque Han; Jeong-Im Sin
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

9.  Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain.

Authors:  E Sloane; S Langer; B Jekich; J Mahoney; T Hughes; M Frank; W Seibert; G Huberty; B Coats; J Harrison; D Klinman; S Poole; S Maier; K Johnson; R Chavez; L R Watkins; L Leinwand; E Milligan
Journal:  Gene Ther       Date:  2009-07-02       Impact factor: 5.250

10.  Cancer immunotherapy using the Fusion gene of Sendai virus.

Authors:  Jiayu A Tai; Chin Yang Chang; Tomoyuki Nishikawa; Yasufumi Kaneda
Journal:  Cancer Gene Ther       Date:  2019-08-06       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.